32 results
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
6 Jun 24
Report of Foreign Private Issuer
5:00pm
of the members of the Compensation, Nomination and Governance Committee
Proposal
The Board of Directors proposes that Ronald Hafner and Gian-Marco Rinaldi Diaz … de la Cruz shall be re-elected as members of the Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary
424B5
NLSP
NLS Pharmaceutics Ltd
22 Mar 24
Prospectus supplement for primary offering
10:24am
, the members of the compensation, nomination and governance committee, the auditors and the independent proxy holder (a person annually elected by the general
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
9 Jun 23
Report of Foreign Private Issuer
8:30am
shareholders’ meeting.
Re-election and new election of the members of the Compensation, Nomination and Governance Committee
Proposal
The Board of Directors … , Nomination and Governance Committee for a term lasting until the next annual ordinary shareholders’ meeting.
Re-election of the Auditors
Proposal
6-K
EX-99.1
a0cdy
11 May 22
Report of Foreign Private Issuer
5:00pm
424B5
jfecu
14 Apr 22
Prospectus supplement for primary offering
4:48pm
6-K
EX-99.1
wr5ew3vr11t pmx
6 Apr 22
Investor Presentation | April 2022 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies
5:14pm
424B5
ku518dki
4 Mar 22
Prospectus supplement for primary offering
4:01pm
F-3
hwi7aco7zb u0on
3 Feb 22
Shelf registration (foreign)
4:00pm
F-1
x51e td15cn
20 Dec 21
Registration statement (foreign)
4:06pm
F-1/A
vumlpmeed9uc7w31
1 Nov 21
Registration statement (foreign) (amended)
8:30am
F-1
2h5ryd
22 Oct 21
Registration statement (foreign)
4:02pm
POS AM
wbh4ouhxr9vad
30 Sep 21
Prospectus update (post-effective amendment)
4:00pm
6-K
EX-99.1
lcb7fzxz wm
6 Jul 21
Investor Presentation | July 2021 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies
4:06pm
POS AM
4g9s7x659kjuwm79p5
27 May 21
Prospectus update (post-effective amendment)
5:28pm